Clinical trial · Observational
Anti-mullerian Hormone in Acute Lymphoblastic Leukemia
Anti-mullerian Hormone in Pediatric Patients Treated for Acute Lymphoblastic Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with current survival rates exceeding 90%. As cure rates improve, increasing attention is focused on survivor quality of life, including fertility. It is generally accepted that cancer treatments in childhood may interfere with gonadal function, reducing the pool of primordial follicles and consequently causing premature menopause in women. Anti-Mullerian hormone (AMH) levels is a valuable quantitative indicator of ovarian reserve, being directly related to the number of antral follicles. The evaluation of this hormone makes it possible to identify women at risk of early menopause and to propose them interventions for monitoring and preservation of oocytes, allowing girls to be able to have children once they reach adulthood. The objective of this study is to determine ovarian reserve in girls with ALL before and after treatment by means of the evaluation of the AMH assay.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Evaluation of blood AMH levels before ALL treatment
- timeFrame
- Within one months from ALL diagnosis
- description
- AMH levels will be evaluated in peripheral blood
- measure
- Evaluation of blood AMH levels after ALL treatment
- timeFrame
- 24 months after ALL diagnosis
- description
- AMH levels will be evaluated in peripheral blood
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 1 Month
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female less than 18 years of age * Diagnosis of acute lymphoblastic leukemia * enrollment within the first month after diagnosis Exclusion Criteria: * Previous treatments with cytostatics drugs * ALL as a second malignancy * Syndromic patient or primary hypogonadism
References
Publications (0)
Data not yet available